Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

被引：0
|
作者：
Bridges, J. [1 ]
De La Cruz, M. [2 ]
Pavilack, M. [3 ]
Flood, E. [2 ]
Janssen, E. [2 ]
Chehab, N. [3 ]
Fernandes, A. [3 ]
机构：
[1] Ohio State Univ, Coll Med, Dept Biomed Informat, Columbus, OH 43210 USA
[2] Icon, Gaithersburg, MD USA
[3] Astrazeneca, Med Affairs Oncol, Gaithersburg, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
treatment preference; EGFR-TKI; NSCLC;
D O I：
10.1016/j.jtho.2018.08.288
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10.01
引用
收藏
页码：S343 / S343
页数：1
相关论文
共 50 条
  • [1] Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer
    Bridges, John F. P.
    de la Cruz, Marie
    Pavilack, Melissa
    Flood, Emuella
    Janssen, Ellen M.
    Chehab, Nabil
    Fernandes, Ancilla W.
    FUTURE ONCOLOGY, 2019, 15 (34) : 3895 - 3907
  • [2] Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard, Nicolas
    FUTURE ONCOLOGY, 2018, 14 (11) : 1117 - 1132
  • [3] Efficacy of Tyrosine Kinase Inhibitor for Non-adenocarcinoma NSCLC Patients With EGFR Mutation
    Cho, S. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S620 - S620
  • [4] TREATMENTS FOR EGFR MUTATION POSITIVE NSCLC - A NETWORK META ANALYSIS
    Fonseca, T.
    Lungershausen, J.
    Wallenstein, G.
    Stammberger, U.
    Bertwistle, D.
    Griebsch, I
    VALUE IN HEALTH, 2013, 16 (07) : A396 - A396
  • [5] Patterns of Failure in Metastatic and/or Recurrent EGFR Mutation Positive NSCLC
    Orban, M. W.
    Kelly, P.
    Tseng, J.
    Johnson, T.
    Manon, R.
    Rostorfer, R.
    Rineer, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E445 - E446
  • [6] Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
    Sung, Mike R.
    Tomasini, Pascale
    Le, Lisa W.
    Kamel-Reid, Suzanne
    Tsao, Ming-Sound
    Liu, Geoffrey
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Li, Janice J. N.
    Feld, Ronald
    Leighl, Natasha B.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
  • [7] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [8] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Cho, Su-Hee
    Park, Lee Chun
    Ji, Jun Ho
    Park, Silvia
    Hwang, Deok Won
    Lee, Ji Yean
    Choi, Yoon-La
    Han, Jung-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 315 - 320
  • [9] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Su-Hee Cho
    Lee Chun Park
    Jun Ho Ji
    Silvia Park
    Deok Won Hwang
    Ji Yean Lee
    Yoon-La Choi
    Jung-Ho Han
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 315 - 320
  • [10] Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC
    Roeper, Julia
    Kurz, Sylke
    Grohe, Christian
    Griesinger, Frank
    FUTURE ONCOLOGY, 2020, 17 (04) : 471 - 486
12345